TG Therapeutics signs $645M deal to kick-start international launch of MS antibody

TG Therapeutics is looking to expand access to its CD20 antibody Briumvi outside North America and has announced a partnership with the European pharma company Neuraxpharm.

The deal is for $140 million in cash upfront, plus another $12.5 million once the drug, approved in the US and EU for adults with relapsing forms of multiple sclerosis, is launched in the first EU member country, according to a press release Tuesday.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Doctors created a primary care clinic as their former hospital struggled

About a year ago, Valory Wangler, a family medicine doctor, invited a handful of former co-workers to her backyard.

July 21, 2023

Cell and gene therapies – top pharmaceutical industry trend to watch for 2024 – Pharmaceutical Technology

Share this article Cell and gene therapies (CGTs) are gradually becoming an important focus within the healthcare industry. While this is a relatively new development—as the

January 29, 2024

FTC issues warnings on ‘junk’ patent listings for Ozempic and other drugs

The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments

April 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.